Access to Medicines
KEI Documents and commentary regarding Hepatitis C Virus (HCV) related issues
- July 18, 2014. "Non-voluntary use of patents for drugs to treat the Hepatitis C Virus in the United States: Mechanisms available to the Federal Government, State Governments and Private Actors."
A policy brief examining possible mechanisms to overcome the exclusive rights of patents for drugs to treat the Hepatitis C Virus in the United States.
Civil Society on transparency, public health in TPPA; 28 Senators call for highest standards of protection IP in agreementSubmitted by Krista Cox on 18. May 2011 - 15:32
On Wednesday, May 18, 2011, eight civil society organizations submitted joint comments and recommendations on the Trans-Pacific Partnership Agreement (TPPA).
Today, Tibotec, a subsidiary of Johnson & Johnson, announced it has signed voluntary licensing agreements with several Indian and South African generic companies to allow generic competition on a new HIV-AIDS treatment, the investigational non-nucleoside reverse transcriptase inhibitor rilpivirine hydrochloride (TMC278) (rilpivirine hydrochloride), to certain developing countries.
I was recently asked the following question:
What is your view on the treatment of prize funds? By all standards it is treated as a radical off the wall proposal when in fact it is market based. Why is there so much resistance?
My response was as follows:
On December 9, 2009, Wikileaks posted five sensitive documents related to the WHO Expert Working Group (EWG) on R&D Financing:
a non-public draft report of the WHO EWG a non-public Comparative Analysis done by the EWG the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) Overview of the EWG Comparative Analysis an IFPMA summary slide on the EWG Draft Report
The following is a letter sent by Cecilia López Montaño, a member of the WHO Expert Working Group on R&D Financing to the WHO Executive Board:
Dear members of the Executive Board:
I am Cecilia López Montaño, senator of the Colombian Congress and member of the Expert Working Group on Research and Development Financing of the World Health Organization, in representation of the point of view of developing countries, I assume.
Can the U.S. realistically honor commitments to fund treatment for AIDS in developing countries without generic products?Submitted by James Love on 12. January 2010 - 22:34
On Monday, December 14, the UNITAID board passed a resolution to establish a Patent Pool for AIDS medicines. The decision caped a dramatic debate on the proposal, which had been before UNITAID since 2006, and had been discussed in other fora since 2002. The following is a statement by KEI on the UNITAID decision, followed by background on the UNITAID patent pool proposal, including a copy of the UNITAID press release.
Statement of James Love, Director of KEI, on the UNITAID Patent Pool:
Speech of Mike Foster, UK Minister for International Development at launch of Industry Government Forum on Access to MedicinesSubmitted by thiru on 21. October 2009 - 4:32
On October 12, 2009, the "Industry Government Forum on Access to Medicines" (IGFAM) was launched. The UK Minister for International Development, MP Mike Foster made a a speech to launch this initiative which is reproduced below.
Presentations were also made by Pfizer (Ponni Subbiah), GSK (Abbas Hussain), Rajiv Venkayya (Gates Foundation), Prashant Yadav (Massachusetts Institute of Technology) and Suerie Moon (Research Fellow and Doctoral Candidate, Kennedy School of Government, Harvard University).